The role of radioactive iodine in the management of patients with differentiated thyroid cancer – An oncologic surgical perspective
With improved understanding of the biology of differentiated thyroid carcinoma its management is evolving. The approach to surgery for the primary tumour and elective nodal surgery is moving from a “one-size-fits-all” recommendation to a more personalised approach based on risk group stratification....
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Nixon, I.J. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2020transfer abstract |
|---|
| Schlagwörter: |
|---|
| Umfang: |
9 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Updated insight into the role of Th2-associated immunity in systemic lupus erythematosus - Wang, Hui ELSEVIER, 2022, Burlington, Mass |
|---|---|
| Übergeordnetes Werk: |
volume:46 ; year:2020 ; number:5 ; pages:754-762 ; extent:9 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.ejso.2020.01.010 |
|---|
| Katalog-ID: |
ELV049971840 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV049971840 | ||
| 003 | DE-627 | ||
| 005 | 20230626025534.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200518s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejso.2020.01.010 |2 doi | |
| 028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001083.pica |
| 035 | |a (DE-627)ELV049971840 | ||
| 035 | |a (ELSEVIER)S0748-7983(20)30014-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.45 |2 bkl | ||
| 100 | 1 | |a Nixon, I.J. |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The role of radioactive iodine in the management of patients with differentiated thyroid cancer – An oncologic surgical perspective |
| 264 | 1 | |c 2020transfer abstract | |
| 300 | |a 9 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a With improved understanding of the biology of differentiated thyroid carcinoma its management is evolving. The approach to surgery for the primary tumour and elective nodal surgery is moving from a “one-size-fits-all” recommendation to a more personalised approach based on risk group stratification. With this selective approach to initial surgery, the indications for adjuvant radioactive iodine (RAI) therapy are also changing. This selective approach to adjuvant therapy requires understanding by the entire treatment team of the rationale for RAI, the potential for benefit, the limitations of the evidence, and the potential for side-effects. | ||
| 520 | |a With improved understanding of the biology of differentiated thyroid carcinoma its management is evolving. The approach to surgery for the primary tumour and elective nodal surgery is moving from a “one-size-fits-all” recommendation to a more personalised approach based on risk group stratification. With this selective approach to initial surgery, the indications for adjuvant radioactive iodine (RAI) therapy are also changing. This selective approach to adjuvant therapy requires understanding by the entire treatment team of the rationale for RAI, the potential for benefit, the limitations of the evidence, and the potential for side-effects. | ||
| 650 | 7 | |a Thyroid cancer |2 Elsevier | |
| 650 | 7 | |a Radioactive iodine |2 Elsevier | |
| 650 | 7 | |a Adjuvant |2 Elsevier | |
| 650 | 7 | |a Thyroidectomy |2 Elsevier | |
| 700 | 1 | |a Shah, J.P. |4 oth | |
| 700 | 1 | |a Zafereo, M. |4 oth | |
| 700 | 1 | |a Simo, R.S. |4 oth | |
| 700 | 1 | |a Hay, I.D. |4 oth | |
| 700 | 1 | |a Suárez, C. |4 oth | |
| 700 | 1 | |a Zbären, P. |4 oth | |
| 700 | 1 | |a Rinaldo, A. |4 oth | |
| 700 | 1 | |a Sanabria, A. |4 oth | |
| 700 | 1 | |a Silver, C. |4 oth | |
| 700 | 1 | |a Mäkitie, A. |4 oth | |
| 700 | 1 | |a Vander Poorten, V. |4 oth | |
| 700 | 1 | |a Kowalski, L.P. |4 oth | |
| 700 | 1 | |a Shaha, A.R. |4 oth | |
| 700 | 1 | |a Randolph, G.W. |4 oth | |
| 700 | 1 | |a Ferlito, A. |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Harcourt |a Wang, Hui ELSEVIER |t Updated insight into the role of Th2-associated immunity in systemic lupus erythematosus |d 2022 |g Burlington, Mass |w (DE-627)ELV008984085 |
| 773 | 1 | 8 | |g volume:46 |g year:2020 |g number:5 |g pages:754-762 |g extent:9 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ejso.2020.01.010 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.45 |j Immunologie |q VZ |
| 951 | |a AR | ||
| 952 | |d 46 |j 2020 |e 5 |h 754-762 |g 9 | ||
| author_variant |
i n in |
|---|---|
| matchkey_str |
nixonijshahjpzafereomsimorshayidsurezczb:2020----:hrlordocieoienhmngmnoptetwtdfeetaetyodacrn |
| hierarchy_sort_str |
2020transfer abstract |
| bklnumber |
44.45 |
| publishDate |
2020 |
| allfields |
10.1016/j.ejso.2020.01.010 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001083.pica (DE-627)ELV049971840 (ELSEVIER)S0748-7983(20)30014-7 DE-627 ger DE-627 rakwb eng 610 VZ 44.45 bkl Nixon, I.J. verfasserin aut The role of radioactive iodine in the management of patients with differentiated thyroid cancer – An oncologic surgical perspective 2020transfer abstract 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier With improved understanding of the biology of differentiated thyroid carcinoma its management is evolving. The approach to surgery for the primary tumour and elective nodal surgery is moving from a “one-size-fits-all” recommendation to a more personalised approach based on risk group stratification. With this selective approach to initial surgery, the indications for adjuvant radioactive iodine (RAI) therapy are also changing. This selective approach to adjuvant therapy requires understanding by the entire treatment team of the rationale for RAI, the potential for benefit, the limitations of the evidence, and the potential for side-effects. With improved understanding of the biology of differentiated thyroid carcinoma its management is evolving. The approach to surgery for the primary tumour and elective nodal surgery is moving from a “one-size-fits-all” recommendation to a more personalised approach based on risk group stratification. With this selective approach to initial surgery, the indications for adjuvant radioactive iodine (RAI) therapy are also changing. This selective approach to adjuvant therapy requires understanding by the entire treatment team of the rationale for RAI, the potential for benefit, the limitations of the evidence, and the potential for side-effects. Thyroid cancer Elsevier Radioactive iodine Elsevier Adjuvant Elsevier Thyroidectomy Elsevier Shah, J.P. oth Zafereo, M. oth Simo, R.S. oth Hay, I.D. oth Suárez, C. oth Zbären, P. oth Rinaldo, A. oth Sanabria, A. oth Silver, C. oth Mäkitie, A. oth Vander Poorten, V. oth Kowalski, L.P. oth Shaha, A.R. oth Randolph, G.W. oth Ferlito, A. oth Enthalten in Harcourt Wang, Hui ELSEVIER Updated insight into the role of Th2-associated immunity in systemic lupus erythematosus 2022 Burlington, Mass (DE-627)ELV008984085 volume:46 year:2020 number:5 pages:754-762 extent:9 https://doi.org/10.1016/j.ejso.2020.01.010 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.45 Immunologie VZ AR 46 2020 5 754-762 9 |
| spelling |
10.1016/j.ejso.2020.01.010 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001083.pica (DE-627)ELV049971840 (ELSEVIER)S0748-7983(20)30014-7 DE-627 ger DE-627 rakwb eng 610 VZ 44.45 bkl Nixon, I.J. verfasserin aut The role of radioactive iodine in the management of patients with differentiated thyroid cancer – An oncologic surgical perspective 2020transfer abstract 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier With improved understanding of the biology of differentiated thyroid carcinoma its management is evolving. The approach to surgery for the primary tumour and elective nodal surgery is moving from a “one-size-fits-all” recommendation to a more personalised approach based on risk group stratification. With this selective approach to initial surgery, the indications for adjuvant radioactive iodine (RAI) therapy are also changing. This selective approach to adjuvant therapy requires understanding by the entire treatment team of the rationale for RAI, the potential for benefit, the limitations of the evidence, and the potential for side-effects. With improved understanding of the biology of differentiated thyroid carcinoma its management is evolving. The approach to surgery for the primary tumour and elective nodal surgery is moving from a “one-size-fits-all” recommendation to a more personalised approach based on risk group stratification. With this selective approach to initial surgery, the indications for adjuvant radioactive iodine (RAI) therapy are also changing. This selective approach to adjuvant therapy requires understanding by the entire treatment team of the rationale for RAI, the potential for benefit, the limitations of the evidence, and the potential for side-effects. Thyroid cancer Elsevier Radioactive iodine Elsevier Adjuvant Elsevier Thyroidectomy Elsevier Shah, J.P. oth Zafereo, M. oth Simo, R.S. oth Hay, I.D. oth Suárez, C. oth Zbären, P. oth Rinaldo, A. oth Sanabria, A. oth Silver, C. oth Mäkitie, A. oth Vander Poorten, V. oth Kowalski, L.P. oth Shaha, A.R. oth Randolph, G.W. oth Ferlito, A. oth Enthalten in Harcourt Wang, Hui ELSEVIER Updated insight into the role of Th2-associated immunity in systemic lupus erythematosus 2022 Burlington, Mass (DE-627)ELV008984085 volume:46 year:2020 number:5 pages:754-762 extent:9 https://doi.org/10.1016/j.ejso.2020.01.010 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.45 Immunologie VZ AR 46 2020 5 754-762 9 |
| allfields_unstemmed |
10.1016/j.ejso.2020.01.010 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001083.pica (DE-627)ELV049971840 (ELSEVIER)S0748-7983(20)30014-7 DE-627 ger DE-627 rakwb eng 610 VZ 44.45 bkl Nixon, I.J. verfasserin aut The role of radioactive iodine in the management of patients with differentiated thyroid cancer – An oncologic surgical perspective 2020transfer abstract 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier With improved understanding of the biology of differentiated thyroid carcinoma its management is evolving. The approach to surgery for the primary tumour and elective nodal surgery is moving from a “one-size-fits-all” recommendation to a more personalised approach based on risk group stratification. With this selective approach to initial surgery, the indications for adjuvant radioactive iodine (RAI) therapy are also changing. This selective approach to adjuvant therapy requires understanding by the entire treatment team of the rationale for RAI, the potential for benefit, the limitations of the evidence, and the potential for side-effects. With improved understanding of the biology of differentiated thyroid carcinoma its management is evolving. The approach to surgery for the primary tumour and elective nodal surgery is moving from a “one-size-fits-all” recommendation to a more personalised approach based on risk group stratification. With this selective approach to initial surgery, the indications for adjuvant radioactive iodine (RAI) therapy are also changing. This selective approach to adjuvant therapy requires understanding by the entire treatment team of the rationale for RAI, the potential for benefit, the limitations of the evidence, and the potential for side-effects. Thyroid cancer Elsevier Radioactive iodine Elsevier Adjuvant Elsevier Thyroidectomy Elsevier Shah, J.P. oth Zafereo, M. oth Simo, R.S. oth Hay, I.D. oth Suárez, C. oth Zbären, P. oth Rinaldo, A. oth Sanabria, A. oth Silver, C. oth Mäkitie, A. oth Vander Poorten, V. oth Kowalski, L.P. oth Shaha, A.R. oth Randolph, G.W. oth Ferlito, A. oth Enthalten in Harcourt Wang, Hui ELSEVIER Updated insight into the role of Th2-associated immunity in systemic lupus erythematosus 2022 Burlington, Mass (DE-627)ELV008984085 volume:46 year:2020 number:5 pages:754-762 extent:9 https://doi.org/10.1016/j.ejso.2020.01.010 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.45 Immunologie VZ AR 46 2020 5 754-762 9 |
| allfieldsGer |
10.1016/j.ejso.2020.01.010 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001083.pica (DE-627)ELV049971840 (ELSEVIER)S0748-7983(20)30014-7 DE-627 ger DE-627 rakwb eng 610 VZ 44.45 bkl Nixon, I.J. verfasserin aut The role of radioactive iodine in the management of patients with differentiated thyroid cancer – An oncologic surgical perspective 2020transfer abstract 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier With improved understanding of the biology of differentiated thyroid carcinoma its management is evolving. The approach to surgery for the primary tumour and elective nodal surgery is moving from a “one-size-fits-all” recommendation to a more personalised approach based on risk group stratification. With this selective approach to initial surgery, the indications for adjuvant radioactive iodine (RAI) therapy are also changing. This selective approach to adjuvant therapy requires understanding by the entire treatment team of the rationale for RAI, the potential for benefit, the limitations of the evidence, and the potential for side-effects. With improved understanding of the biology of differentiated thyroid carcinoma its management is evolving. The approach to surgery for the primary tumour and elective nodal surgery is moving from a “one-size-fits-all” recommendation to a more personalised approach based on risk group stratification. With this selective approach to initial surgery, the indications for adjuvant radioactive iodine (RAI) therapy are also changing. This selective approach to adjuvant therapy requires understanding by the entire treatment team of the rationale for RAI, the potential for benefit, the limitations of the evidence, and the potential for side-effects. Thyroid cancer Elsevier Radioactive iodine Elsevier Adjuvant Elsevier Thyroidectomy Elsevier Shah, J.P. oth Zafereo, M. oth Simo, R.S. oth Hay, I.D. oth Suárez, C. oth Zbären, P. oth Rinaldo, A. oth Sanabria, A. oth Silver, C. oth Mäkitie, A. oth Vander Poorten, V. oth Kowalski, L.P. oth Shaha, A.R. oth Randolph, G.W. oth Ferlito, A. oth Enthalten in Harcourt Wang, Hui ELSEVIER Updated insight into the role of Th2-associated immunity in systemic lupus erythematosus 2022 Burlington, Mass (DE-627)ELV008984085 volume:46 year:2020 number:5 pages:754-762 extent:9 https://doi.org/10.1016/j.ejso.2020.01.010 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.45 Immunologie VZ AR 46 2020 5 754-762 9 |
| allfieldsSound |
10.1016/j.ejso.2020.01.010 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001083.pica (DE-627)ELV049971840 (ELSEVIER)S0748-7983(20)30014-7 DE-627 ger DE-627 rakwb eng 610 VZ 44.45 bkl Nixon, I.J. verfasserin aut The role of radioactive iodine in the management of patients with differentiated thyroid cancer – An oncologic surgical perspective 2020transfer abstract 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier With improved understanding of the biology of differentiated thyroid carcinoma its management is evolving. The approach to surgery for the primary tumour and elective nodal surgery is moving from a “one-size-fits-all” recommendation to a more personalised approach based on risk group stratification. With this selective approach to initial surgery, the indications for adjuvant radioactive iodine (RAI) therapy are also changing. This selective approach to adjuvant therapy requires understanding by the entire treatment team of the rationale for RAI, the potential for benefit, the limitations of the evidence, and the potential for side-effects. With improved understanding of the biology of differentiated thyroid carcinoma its management is evolving. The approach to surgery for the primary tumour and elective nodal surgery is moving from a “one-size-fits-all” recommendation to a more personalised approach based on risk group stratification. With this selective approach to initial surgery, the indications for adjuvant radioactive iodine (RAI) therapy are also changing. This selective approach to adjuvant therapy requires understanding by the entire treatment team of the rationale for RAI, the potential for benefit, the limitations of the evidence, and the potential for side-effects. Thyroid cancer Elsevier Radioactive iodine Elsevier Adjuvant Elsevier Thyroidectomy Elsevier Shah, J.P. oth Zafereo, M. oth Simo, R.S. oth Hay, I.D. oth Suárez, C. oth Zbären, P. oth Rinaldo, A. oth Sanabria, A. oth Silver, C. oth Mäkitie, A. oth Vander Poorten, V. oth Kowalski, L.P. oth Shaha, A.R. oth Randolph, G.W. oth Ferlito, A. oth Enthalten in Harcourt Wang, Hui ELSEVIER Updated insight into the role of Th2-associated immunity in systemic lupus erythematosus 2022 Burlington, Mass (DE-627)ELV008984085 volume:46 year:2020 number:5 pages:754-762 extent:9 https://doi.org/10.1016/j.ejso.2020.01.010 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.45 Immunologie VZ AR 46 2020 5 754-762 9 |
| language |
English |
| source |
Enthalten in Updated insight into the role of Th2-associated immunity in systemic lupus erythematosus Burlington, Mass volume:46 year:2020 number:5 pages:754-762 extent:9 |
| sourceStr |
Enthalten in Updated insight into the role of Th2-associated immunity in systemic lupus erythematosus Burlington, Mass volume:46 year:2020 number:5 pages:754-762 extent:9 |
| format_phy_str_mv |
Article |
| bklname |
Immunologie |
| institution |
findex.gbv.de |
| topic_facet |
Thyroid cancer Radioactive iodine Adjuvant Thyroidectomy |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Updated insight into the role of Th2-associated immunity in systemic lupus erythematosus |
| authorswithroles_txt_mv |
Nixon, I.J. @@aut@@ Shah, J.P. @@oth@@ Zafereo, M. @@oth@@ Simo, R.S. @@oth@@ Hay, I.D. @@oth@@ Suárez, C. @@oth@@ Zbären, P. @@oth@@ Rinaldo, A. @@oth@@ Sanabria, A. @@oth@@ Silver, C. @@oth@@ Mäkitie, A. @@oth@@ Vander Poorten, V. @@oth@@ Kowalski, L.P. @@oth@@ Shaha, A.R. @@oth@@ Randolph, G.W. @@oth@@ Ferlito, A. @@oth@@ |
| publishDateDaySort_date |
2020-01-01T00:00:00Z |
| hierarchy_top_id |
ELV008984085 |
| dewey-sort |
3610 |
| id |
ELV049971840 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV049971840</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626025534.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">200518s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ejso.2020.01.010</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001083.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV049971840</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0748-7983(20)30014-7</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.45</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Nixon, I.J.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The role of radioactive iodine in the management of patients with differentiated thyroid cancer – An oncologic surgical perspective</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">9</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">With improved understanding of the biology of differentiated thyroid carcinoma its management is evolving. The approach to surgery for the primary tumour and elective nodal surgery is moving from a “one-size-fits-all” recommendation to a more personalised approach based on risk group stratification. With this selective approach to initial surgery, the indications for adjuvant radioactive iodine (RAI) therapy are also changing. This selective approach to adjuvant therapy requires understanding by the entire treatment team of the rationale for RAI, the potential for benefit, the limitations of the evidence, and the potential for side-effects.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">With improved understanding of the biology of differentiated thyroid carcinoma its management is evolving. The approach to surgery for the primary tumour and elective nodal surgery is moving from a “one-size-fits-all” recommendation to a more personalised approach based on risk group stratification. With this selective approach to initial surgery, the indications for adjuvant radioactive iodine (RAI) therapy are also changing. This selective approach to adjuvant therapy requires understanding by the entire treatment team of the rationale for RAI, the potential for benefit, the limitations of the evidence, and the potential for side-effects.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Thyroid cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Radioactive iodine</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Adjuvant</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Thyroidectomy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shah, J.P.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zafereo, M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Simo, R.S.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hay, I.D.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Suárez, C.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zbären, P.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rinaldo, A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sanabria, A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Silver, C.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mäkitie, A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vander Poorten, V.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kowalski, L.P.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shaha, A.R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Randolph, G.W.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ferlito, A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Harcourt</subfield><subfield code="a">Wang, Hui ELSEVIER</subfield><subfield code="t">Updated insight into the role of Th2-associated immunity in systemic lupus erythematosus</subfield><subfield code="d">2022</subfield><subfield code="g">Burlington, Mass</subfield><subfield code="w">(DE-627)ELV008984085</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:46</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:5</subfield><subfield code="g">pages:754-762</subfield><subfield code="g">extent:9</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ejso.2020.01.010</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.45</subfield><subfield code="j">Immunologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">46</subfield><subfield code="j">2020</subfield><subfield code="e">5</subfield><subfield code="h">754-762</subfield><subfield code="g">9</subfield></datafield></record></collection>
|
| author |
Nixon, I.J. |
| spellingShingle |
Nixon, I.J. ddc 610 bkl 44.45 Elsevier Thyroid cancer Elsevier Radioactive iodine Elsevier Adjuvant Elsevier Thyroidectomy The role of radioactive iodine in the management of patients with differentiated thyroid cancer – An oncologic surgical perspective |
| authorStr |
Nixon, I.J. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV008984085 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 VZ 44.45 bkl The role of radioactive iodine in the management of patients with differentiated thyroid cancer – An oncologic surgical perspective Thyroid cancer Elsevier Radioactive iodine Elsevier Adjuvant Elsevier Thyroidectomy Elsevier |
| topic |
ddc 610 bkl 44.45 Elsevier Thyroid cancer Elsevier Radioactive iodine Elsevier Adjuvant Elsevier Thyroidectomy |
| topic_unstemmed |
ddc 610 bkl 44.45 Elsevier Thyroid cancer Elsevier Radioactive iodine Elsevier Adjuvant Elsevier Thyroidectomy |
| topic_browse |
ddc 610 bkl 44.45 Elsevier Thyroid cancer Elsevier Radioactive iodine Elsevier Adjuvant Elsevier Thyroidectomy |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
j s js m z mz r s rs i h ih c s cs p z pz a r ar a s as c s cs a m am p v v pv pvv l k lk a s as g r gr a f af |
| hierarchy_parent_title |
Updated insight into the role of Th2-associated immunity in systemic lupus erythematosus |
| hierarchy_parent_id |
ELV008984085 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
Updated insight into the role of Th2-associated immunity in systemic lupus erythematosus |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV008984085 |
| title |
The role of radioactive iodine in the management of patients with differentiated thyroid cancer – An oncologic surgical perspective |
| ctrlnum |
(DE-627)ELV049971840 (ELSEVIER)S0748-7983(20)30014-7 |
| title_full |
The role of radioactive iodine in the management of patients with differentiated thyroid cancer – An oncologic surgical perspective |
| author_sort |
Nixon, I.J. |
| journal |
Updated insight into the role of Th2-associated immunity in systemic lupus erythematosus |
| journalStr |
Updated insight into the role of Th2-associated immunity in systemic lupus erythematosus |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2020 |
| contenttype_str_mv |
zzz |
| container_start_page |
754 |
| author_browse |
Nixon, I.J. |
| container_volume |
46 |
| physical |
9 |
| class |
610 VZ 44.45 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Nixon, I.J. |
| doi_str_mv |
10.1016/j.ejso.2020.01.010 |
| dewey-full |
610 |
| title_sort |
role of radioactive iodine in the management of patients with differentiated thyroid cancer – an oncologic surgical perspective |
| title_auth |
The role of radioactive iodine in the management of patients with differentiated thyroid cancer – An oncologic surgical perspective |
| abstract |
With improved understanding of the biology of differentiated thyroid carcinoma its management is evolving. The approach to surgery for the primary tumour and elective nodal surgery is moving from a “one-size-fits-all” recommendation to a more personalised approach based on risk group stratification. With this selective approach to initial surgery, the indications for adjuvant radioactive iodine (RAI) therapy are also changing. This selective approach to adjuvant therapy requires understanding by the entire treatment team of the rationale for RAI, the potential for benefit, the limitations of the evidence, and the potential for side-effects. |
| abstractGer |
With improved understanding of the biology of differentiated thyroid carcinoma its management is evolving. The approach to surgery for the primary tumour and elective nodal surgery is moving from a “one-size-fits-all” recommendation to a more personalised approach based on risk group stratification. With this selective approach to initial surgery, the indications for adjuvant radioactive iodine (RAI) therapy are also changing. This selective approach to adjuvant therapy requires understanding by the entire treatment team of the rationale for RAI, the potential for benefit, the limitations of the evidence, and the potential for side-effects. |
| abstract_unstemmed |
With improved understanding of the biology of differentiated thyroid carcinoma its management is evolving. The approach to surgery for the primary tumour and elective nodal surgery is moving from a “one-size-fits-all” recommendation to a more personalised approach based on risk group stratification. With this selective approach to initial surgery, the indications for adjuvant radioactive iodine (RAI) therapy are also changing. This selective approach to adjuvant therapy requires understanding by the entire treatment team of the rationale for RAI, the potential for benefit, the limitations of the evidence, and the potential for side-effects. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
| container_issue |
5 |
| title_short |
The role of radioactive iodine in the management of patients with differentiated thyroid cancer – An oncologic surgical perspective |
| url |
https://doi.org/10.1016/j.ejso.2020.01.010 |
| remote_bool |
true |
| author2 |
Shah, J.P. Zafereo, M. Simo, R.S. Hay, I.D. Suárez, C. Zbären, P. Rinaldo, A. Sanabria, A. Silver, C. Mäkitie, A. Vander Poorten, V. Kowalski, L.P. Shaha, A.R. Randolph, G.W. Ferlito, A. |
| author2Str |
Shah, J.P. Zafereo, M. Simo, R.S. Hay, I.D. Suárez, C. Zbären, P. Rinaldo, A. Sanabria, A. Silver, C. Mäkitie, A. Vander Poorten, V. Kowalski, L.P. Shaha, A.R. Randolph, G.W. Ferlito, A. |
| ppnlink |
ELV008984085 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.ejso.2020.01.010 |
| up_date |
2024-07-06T23:02:50.338Z |
| _version_ |
1803872601730187264 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV049971840</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626025534.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">200518s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ejso.2020.01.010</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001083.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV049971840</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0748-7983(20)30014-7</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.45</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Nixon, I.J.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The role of radioactive iodine in the management of patients with differentiated thyroid cancer – An oncologic surgical perspective</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">9</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">With improved understanding of the biology of differentiated thyroid carcinoma its management is evolving. The approach to surgery for the primary tumour and elective nodal surgery is moving from a “one-size-fits-all” recommendation to a more personalised approach based on risk group stratification. With this selective approach to initial surgery, the indications for adjuvant radioactive iodine (RAI) therapy are also changing. This selective approach to adjuvant therapy requires understanding by the entire treatment team of the rationale for RAI, the potential for benefit, the limitations of the evidence, and the potential for side-effects.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">With improved understanding of the biology of differentiated thyroid carcinoma its management is evolving. The approach to surgery for the primary tumour and elective nodal surgery is moving from a “one-size-fits-all” recommendation to a more personalised approach based on risk group stratification. With this selective approach to initial surgery, the indications for adjuvant radioactive iodine (RAI) therapy are also changing. This selective approach to adjuvant therapy requires understanding by the entire treatment team of the rationale for RAI, the potential for benefit, the limitations of the evidence, and the potential for side-effects.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Thyroid cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Radioactive iodine</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Adjuvant</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Thyroidectomy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shah, J.P.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zafereo, M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Simo, R.S.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hay, I.D.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Suárez, C.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zbären, P.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rinaldo, A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sanabria, A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Silver, C.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mäkitie, A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vander Poorten, V.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kowalski, L.P.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shaha, A.R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Randolph, G.W.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ferlito, A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Harcourt</subfield><subfield code="a">Wang, Hui ELSEVIER</subfield><subfield code="t">Updated insight into the role of Th2-associated immunity in systemic lupus erythematosus</subfield><subfield code="d">2022</subfield><subfield code="g">Burlington, Mass</subfield><subfield code="w">(DE-627)ELV008984085</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:46</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:5</subfield><subfield code="g">pages:754-762</subfield><subfield code="g">extent:9</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ejso.2020.01.010</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.45</subfield><subfield code="j">Immunologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">46</subfield><subfield code="j">2020</subfield><subfield code="e">5</subfield><subfield code="h">754-762</subfield><subfield code="g">9</subfield></datafield></record></collection>
|
| score |
7.4028378 |